Diagnostics and Sample Management Growth“Q2 demonstrated that transition beginning to take shape through stronger revenue, improving margins, and meaningful innovation milestones,” Eglinton Manner said. Eglinton Manner said the company expects to provide additional details on localization initiatives later this year. Management reiterated its expectation to reach break-even cash flow from operations as it enters 2027, supported by anticipated revenue growth, new product launches, cost savings and operating efficiencies. For the third quarter, OraSure projected revenue of $29.5 million to $32.5 million and said gross margin is expected to be similar to the second quarter. About OraSure Technologies (NASDAQ:OSUR)OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products.